NCT05293249 - dMAbs for Prevention of COVID-19 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 19, 2022

Primary Completion Date

June 11, 2025

Study Completion Date

December 31, 2025

Conditions

Healthy Volunteers

Interventions

COMBINATION_PRODUCT

dMAb AZD5396

Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

COMBINATION_PRODUCT

dMAb AZD8076

Participants will receive one injection of dMAb AZD8076 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.

COMBINATION_PRODUCT

CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device

The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.

DRUG

Hylenex

Hylenex® recombinant will be used for dMAb AZD5396 and dMAb AZD8076 dose preparation at the clinical site.

COMBINATION_PRODUCT

CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device

The device will be used to perform electroporation (EP) on each subject immediately after being dosed with dMAb AZD5396 and dMAb AZD8076.

Trial Locations (1)

University of Pennsylvania, Philadelphia